Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd Strides Pharma Science Ltd - 532531 - Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 04, 2022 for Pronomz Ventures LLP and Arun Kumar Pillai Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 03, 2022 for Pronomz Ventures LLP and Arun Kumar Pillai Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 22, 2022 for Pronomz Ventures LLP
Strides Pharma arm gets USFDA nod to market Amantadine Hydrochloride Softgel Capsules in America
The company's step-down wholly-owned subsidiary, Strides Pharma Global Pte Ltd Singapore, has received approval from the US Food and Drug Administration (USFDA) for the medication, the company said in a statement. Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
'Strides receives USFDA approval for Amantadine Hydrochloride Softgel Capsules' Strides Pharma Science Ltd - 532531 - Intimation Regarding Rescheduling Of Extraordinary General Meeting
Intimation regarding rescheduling of Extraordinary General Meeting Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding request received for issue of duplicate share certificate under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Gagan Parakh Strides Pharma Q3 net loss at Rs 127 crore
The company had posted a consolidated net profit of Rs 35.15 crore in the October-December period of the previous fiscal. Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement
Intimation of Scheme of Amalgamation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015